Get started
Ginkgo Bioworks Holdings, Inc.Ginkgo Bioworks Holdings, Inc.Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

DNA chart


Full chart

DNA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪471.23 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−10.62 USD
Net income (FY)
‪−547.03 M‬ USD
Revenue (FY)
‪227.04 M‬ USD
Shares float
‪36.98 M‬
Beta (1Y)
2.86

Employees


Employees (FY)
834
Change (1Y)
−384 −31.53%
Revenue / Employee (1Y)
‪272.23 K‬ USD
Net income / Employee (1Y)
‪−655.91 K‬ USD

About Ginkgo Bioworks Holdings, Inc.


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Jason Kelly
Website
ginkgo.bio
Headquarters
Boston
Founded
2008
FIGI
BBG00YPS1KY3
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

DNA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as DNA.

Frequently Asked Questions


The current price of DNA is 8.36 USD — it has increased by 2.96% in the past 24 hours. Watch Ginkgo Bioworks Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Ginkgo Bioworks Holdings, Inc. stocks are traded under the ticker DNA.
DNA stock has risen by 62.02% compared to the previous week, the month change is a 23.67% rise, over the last year Ginkgo Bioworks Holdings, Inc. has showed a −80.28% decrease.
We've gathered analysts' opinions on Ginkgo Bioworks Holdings, Inc. future price: according to them, DNA price has a max estimate of 12.00 USD and a min estimate of 5.50 USD. Watch DNA chart and read a more detailed Ginkgo Bioworks Holdings, Inc. stock forecast: see what analysts think of Ginkgo Bioworks Holdings, Inc. and suggest that you do with its stocks.
DNA reached its all-time high on Nov 9, 2021 with the price of 634.56 USD, and its all-time low was 5.00 USD and was reached on Apr 4, 2025. View more price dynamics on DNA chart.
See other stocks reaching their highest and lowest prices.
DNA stock is 8.59% volatile and has beta coefficient of 2.86. Track Ginkgo Bioworks Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ginkgo Bioworks Holdings, Inc. there?
Today Ginkgo Bioworks Holdings, Inc. has the market capitalization of ‪460.08 M‬, it has increased by 13.25% over the last week.
Yes, you can track Ginkgo Bioworks Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Ginkgo Bioworks Holdings, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
DNA earnings for the last quarter are −2.00 USD per share, whereas the estimation was −1.50 USD resulting in a −32.98% surprise. The estimated earnings for the next quarter are −1.55 USD per share. See more details about Ginkgo Bioworks Holdings, Inc. earnings.
Ginkgo Bioworks Holdings, Inc. revenue for the last quarter amounts to ‪43.85 M‬ USD, despite the estimated figure of ‪44.47 M‬ USD. In the next quarter, revenue is expected to reach ‪39.44 M‬ USD.
DNA net income for the last quarter is ‪−107.53 M‬ USD, while the quarter before that showed ‪−56.40 M‬ USD of net income which accounts for −90.65% change. Track more Ginkgo Bioworks Holdings, Inc. financial stats to get the full picture.
No, DNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 834 employees. See our rating of the largest employees — is Ginkgo Bioworks Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ginkgo Bioworks Holdings, Inc. EBITDA is ‪−399.51 M‬ USD, and current EBITDA margin is −174.98%. See more stats in Ginkgo Bioworks Holdings, Inc. financial statements.
Like other stocks, DNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ginkgo Bioworks Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ginkgo Bioworks Holdings, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ginkgo Bioworks Holdings, Inc. stock shows the sell signal. See more of Ginkgo Bioworks Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.